Related Experiment Video

Updated: May 30, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Systemic therapies for metastatic renal cell carcinoma in older adults

Sumanta K Pal1, Ari Vanderwalde, Arti Hurria

  • 1Division of Genitourinary Malignancies, Department of Medical Oncology Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Drugs & Aging
|August 5, 2011
PubMed

Insights

Targeted therapies show similar efficacy in older adults with metastatic renal cell carcinoma (mRCC). Age-related toxicities are manageable, and Comprehensive Geriatric Assessment (CGA) aids treatment decisions for elderly mRCC patients.

Area of Science:

  • Oncology
  • Geriatric Medicine
  • Pharmacology

Background:

  • Targeted therapies have transformed metastatic renal cell carcinoma (mRCC) treatment.
  • Limited data exist comparing targeted therapy efficacy and safety in older versus younger adults.
  • Aging involves physiological changes and increased comorbidities, impacting treatment tolerance.

Purpose of the Study:

  • To assess the safety and efficacy of vascular endothelial growth factor (VEGF)- and mammalian target of rapamycin (mTOR)-directed therapies in older adults with mRCC.
  • To detail age-related toxicity profiles of targeted agents for mRCC.
  • To provide a framework for risk-benefit analysis in elderly mRCC patients.

Main Methods:

  • Review of pivotal clinical trials for VEGF- and mTOR-directed therapies in mRCC.
  • Subset analyses focusing on older adult populations within these trials.
  • Examination of age-related toxicity data for targeted agents.

Main Results:

  • Subset analyses suggest comparable efficacy of targeted therapies in older adults with mRCC.
  • Specific age-related toxicity profiles for VEGF- and mTOR-directed therapies were identified.
  • The benefits and risks of these therapies in older adults were outlined.

Conclusions:

  • Targeted therapies appear effective in older adults with mRCC.
  • Understanding age-related toxicities is crucial for optimizing treatment.
  • Comprehensive Geriatric Assessment (CGA) may enhance treatment evaluation and decision-making for elderly mRCC patients.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...